| Dr Robert Baxter Meek Iii, MD | |
|
600 Ridgely Ave, Suite 110, Annapolis, MD 21401-1001 | |
| (410) 573-9191 | |
| (410) 573-5910 |
| Full Name | Dr Robert Baxter Meek Iii |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 30 Years |
| Location | 600 Ridgely Ave, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316035447 | NPI | - | NPPES |
| 10436001 | Other | CAQH # | |
| 266032600 | Medicaid | MD | |
| 584 AAN | Other | MD | CAREFIRST ID# |
| FN66-0002 | Other | MD | CAREFIRST BCBS |
| 612370-02 | Other | MD | BC/BS RENDERING # |
| 7000203 | Other | MD | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | D0057026 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| University Of Md Baltimore Washington Medical Center | Glen burnie, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Ent | 8527477819 | 4 |
News Archive
Researchers from Indiana University's Center for Health Policy and Professionalism Research (CHPPR) have found that support for government-sponsored health insurance for individuals under age 65 remains virtually the same regardless of how the plan is described or how involved the government would be.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.
A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States - and millions more worldwide - with type 1 or type 2 diabetes.
› Verified 7 days ago
| Entity Name | Robert B. Meek, Iii, Md, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275730673 PECOS PAC ID: 7214914605 Enrollment ID: O20040716000349 |
News Archive
Researchers from Indiana University's Center for Health Policy and Professionalism Research (CHPPR) have found that support for government-sponsored health insurance for individuals under age 65 remains virtually the same regardless of how the plan is described or how involved the government would be.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.
A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States - and millions more worldwide - with type 1 or type 2 diabetes.
› Verified 7 days ago
| Entity Name | Mid-atlantic Ent |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770175978 PECOS PAC ID: 8527477819 Enrollment ID: O20210518001076 |
News Archive
Researchers from Indiana University's Center for Health Policy and Professionalism Research (CHPPR) have found that support for government-sponsored health insurance for individuals under age 65 remains virtually the same regardless of how the plan is described or how involved the government would be.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.
A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States - and millions more worldwide - with type 1 or type 2 diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Baxter Meek Iii, MD 600 Ridgely Ave, Suite 110, Annapolis, MD 21401-1001 Ph: (410) 573-9191 | Dr Robert Baxter Meek Iii, MD 600 Ridgely Ave, Suite 110, Annapolis, MD 21401-1001 Ph: (410) 573-9191 |
News Archive
Researchers from Indiana University's Center for Health Policy and Professionalism Research (CHPPR) have found that support for government-sponsored health insurance for individuals under age 65 remains virtually the same regardless of how the plan is described or how involved the government would be.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.
A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association's journal Diabetes brings hopeful news to the 18 million people in the United States - and millions more worldwide - with type 1 or type 2 diabetes.
› Verified 7 days ago
Dr. Henry Daniel Sandel Iv, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 127 Lubrano Dr, Suite 102, Annapolis, MD 21401 Phone: 410-266-7120 Fax: 410-266-6042 | |
Annalisa Debacco Overstreet, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 230, Annapolis, MD 21401 Phone: 410-266-3900 Fax: 410-266-9245 | |
Dr. Kevin Shaigany, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 230, Annapolis, MD 21401 Phone: 410-266-3900 Fax: 410-266-9245 | |
Dr. Emily Drury, DO Otolaryngology Medicare: Medicare Enrolled Practice Location: 600 Ridgely Ave Ste 110, Annapolis, MD 21401 Phone: 410-573-9191 | |
Dr. Namita Murthy, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 2629 Riva Rd Ste 108-109, Annapolis, MD 21401 Phone: 443-333-8083 | |
Douglas Alan Finnegan, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 600 Ridgely Ave, Suite 230, Annapolis, MD 21401 Phone: 410-573-9191 |